Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, the molecular association of HER2 gene mutation with HER2 gene amplification and/or protein expression in cancer tissues has not been clearly defined.
|
29504811 |
2018 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Consistently, we show that the addition of the p110β inhibitor to BYL719 prevents the PIP3 rebound and induces greater antitumor efficacy in HER2-amplified and PIK3CA mutant cancers.
|
25544637 |
2015 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The Cancer Genome Atlas project identified HER2 somatic mutations and gene amplification in 7% of patients with colorectal cancer.
|
26243863 |
2015 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Prevalence and role of HER2 mutations in cancer.
|
30951733 |
2019 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In stratification analysis, these associations consistently manifested in ER-positive breast cancer: in ER positive, PR-positive subtype, genotypes with the six-repeats allele (OR, 1.42; 95% CI, 1.06-1.90), long alleles (OR, 1.77; 95% CI, 1.17-2.67) or a high dose of biallelic repeats (OR, 1.67; 95% CI, 1.19-2.33) were associated with cancer risk; in ER positive, HER2-negative subtype, they were susceptible factors with the ORs being 1.46 (95% CI, 1.06-2.02), 2.06 (95% CI, 1.28-3.32) and 1.85 (95% CI, 1.26-2.71), respectively.
|
22404099 |
2012 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Despite the importance of cancer metastasis in the pathogenesis of cancers, data on the ERBB2 kinase domain mutation in cancer metastasis are lacking.
|
16309427 |
2005 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In addition, our comprehensive evaluation revealed that several <i>ERBB2</i> mutations showed varying sensitivities to ERBB2-targeted inhibitors, and thus, the functional significance of each variant should be interpreted precisely to design the best treatment for each patient.<i>Clin Cancer Res; 24(20); 5112-22.©2018 AACR</i>.
|
29967253 |
2018 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Epidermal growth factor receptor (EGFR) and ErbB2 in particular are mutated in many epithelial tumors, and clinical studies suggest that they play roles in cancer development and progression.
|
19208461 |
2009 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, we did not find a significant association between the distribution of genotypes or alleles and cancer characteristics for the HER2 Ile655Val polymorphism.
|
20026098 |
2010 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To date, no urothelial malignancies appear to have been evaluated for HER-2/neu DNA amplification, mRNA expression and protein overproduction.
|
1942310 |
1991 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Notably, the alterations of HER-2 play an important role in drug resistance, but also have a potential association with the cancer risk.
|
26305917 |
2015 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Overall, we detected somatic cancer-driver events in 11 of 40 (27.5%) IE cases and 13 of 36 (36.1%) DE cases, including hotspot mutations in KRAS, ERBB2, PIK3CA and CTNNB1.
|
30428062 |
2019 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression.
|
31752849 |
2019 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Monoclonal antibodies (mAbs) and small molecule inhibitors targeting EGFR and HER2 tyrosine kinase activities exhibit clinical benefits in the treatment of several types of cancers, but their clinical efficacy is limited by the occurrence of drug resistance.
|
26496898 |
2016 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Hotspot missense mutations on known cancer genes such as ERBB2 and KRAS were largely observed as region-specific aberrations.
|
27175599 |
2016 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A significant risk association of HER-2 Ile655Val polymorphism was observed in different types of cancer using various genetic models (co-dominant heterogeneous Ile/Val vs Ile/Ile; OR=1.1, 95% CI = 1.01-1.16, P = 0.01 and dominant; OR = 1.12, 95% CI = 1.03-1.20, P = 0.0003).
|
27293060 |
2016 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To test the efficacy of Her-2 DNA vaccines in cancer patients, clinical trials have been initiated in phase "C".
|
18273615 |
2008 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2 somatic mutations in cancers lacking HER2 gene amplification.
|
23220880 |
2013 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Human epidermal growth factor receptor 2 (HER2 or ErbB2) can be overexpressed, amplified and/or mutated in malignant tumors, and is a candidate for therapeutic targeting.
|
28146588 |
2017 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to investigate the degree to which HER2 amplification in terms of HER2 gene copy numbers in HER2+IHC2+ cancers affected the outcome in a community setting.
|
24691421 |
2014 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Genetic polymorphism not only affects cancer susceptibility but also influences malignant phenotype; examples include single-nucleotide polymorphism in the HER-2 and MMP-9 genes.
|
15864715 |
2005 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion, using G129R-based fusion proteins to target mammary carcinomas and to tackle multiple hallmarks of cancer at the same time was an effective strategy for treating HER2-postive mammary cancer in this mouse tumor model.
|
19287973 |
2009 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis.
|
30467396 |
2018 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This localization may facilitate the search for human malignancies with chromosome changes involving the erbB-2 gene.
|
2565881 |
1989 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Erratum: A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors.
|
31788108 |
2019 |